Daxor Corporation  

(Public, NYSEMKT:DXR)   Watch this stock  
Find more results for Martin Mombard�
0.00 (0.00%)
Dec 18 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.65 - 8.90
Open     -
Vol / Avg. 100.00/4,899.00
Mkt cap 26.30M
P/E     -
Div/yield 0.03/1.23
EPS -1.07
Shares 5.32M
Beta 0.11
Inst. own 5%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -61.14% -401.38%
Operating margin 58.65% 69.35%
EBITD margin - 69.35%
Return on average assets -2.05% -15.85%
Return on average equity -3.65% -26.73%
Employees 37 -
CDP Score - -


Suite 7120, 350 Fifth Ave.
NEW YORK, NY 10118
United States - Map
+1-212-2440555 (Phone)
+1-212-2440806 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Daxor Corporation is a medical device manufacturing company which provides additional biotechnology services. The Company focuses on the creation and development of the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. This instrument is used in conjunction with Volumex , a single-use radiopharmaceutical diagnostic injection and collection kit. The Company also offers cryobanking services for blood storage through Scientific Medical Systems and for semen storage through Idant, a subsidiary of Scientific Medical Systems. The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee, which manufactures, tests, and develops next-generation models of the BVA-100. In March 2013, Banner Good Samaritan Medical Center of Phoenix, Arizona purchased a BVA-100 Blood Volume Analyzer.

Officers and directors

Joseph Feldschuh M.D. Chairman of the Board, President
Age: 77
Bio & Compensation  - Reuters
James A. Lombard Independent Director
Age: 78
Bio & Compensation  - Reuters
Bernhard Saxe Esq. Independent Director
Age: 74
Bio & Compensation  - Reuters
Robert Willens Independent Director
Age: 65
Bio & Compensation  - Reuters
Martin S. Wolpoff Independent Director
Age: 70
Bio & Compensation  - Reuters